Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE NAMENDA INDIRECT PURCHASER ANTITRUST LITIGATION
Case Number:
1:15-cv-06549
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Cohen & Gresser
- Constantine Cannon
- Crowell & Moring
- Goodwin Procter
- Jones Day
- Kelley Drye
- Kirkland & Ellis
- Labaton Keller
- Pendley Baudin
- Safirstein Law
- Wachtell Lipton
- White & Case
Companies
- Allergan PLC
- Amneal Pharmaceuticals Inc.
- Dr. Reddy's Laboratories Ltd.
- Forest Laboratories Inc.
- J.M. Smith Corp.
- Merz Pharma GmbH & Co KGaA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Upsher-Smith Laboratories Inc.
- Wockhardt Ltd.
- Wockhardt USA LLC
Sectors & Industries:
-
March 24, 2023
Attys Get $18.8M In Allergan, Merz 'Pay-For-Delay' Settlement
Plaintiffs counsel in a class action from consumers who alleged Allergan and Merz delayed generic versions of Alzheimer's drugs from coming to market will be awarded 33.3%, plus litigation expense reimbursement, of an eight-figure settlement.
-
November 14, 2022
Allergan, Merz's $54.4M Nameda Pay-For-Delay Deal Wins OK
A New York federal judge on Monday granted preliminary approval to consumers' $54.4 million settlement with pharmaceutical companies Allergan and Merz over alleged pay-for-delay deals that kept generic versions of the Alzheimer's disease drug Namenda off the market, an agreement reached on the eve of trial.
-
June 11, 2021
Allergan Unit Must Face Bulk Of Namenda Pay-For-Delay Suit
Allergan subsidiary Forest Laboratories LLC must face a jury over a union health and welfare fund's class action antitrust claims that pay-for-delay deals kept generic versions of Alzheimer's drug Namenda off the market after a New York federal judge largely rejected the parties' competing bids for a quick win Friday.
-
September 01, 2020
Dr. Reddy's Inks Deal To Exit Namenda Pay-For-Delay Suit
Drug buyers asked a New York federal court on Monday to approve their deal with generic-drug maker Dr. Reddy's Laboratories to settle class allegations accusing the company of conspiring with other pharma firms to keep a generic version of the brand name Alzheimer's drug Namenda off the market.
-
July 21, 2020
Namenda Buyers Want Cert. In Pay-For-Delay Fight
Drug buyers who claim that a slew of pharmaceutical companies conspired to keep a generic version of the brand name Alzheimer's drug Namenda off the market are asking a New York federal court to sign off on their class action.
-
August 19, 2019
4 Drug Cos. Strike $1.5M Deal In Namenda Pay-For-Delay Suit
Four generic-drug makers have agreed to pay a combined $1.54 million to settle allegations that they struck anticompetitive deals with an Actavis unit to keep a generic version of the Alzheimer's drug Namenda off the market.
-
December 23, 2015
Actavis Says Namenda Product-Hopping Suit Has No Hop
Pharmaceutical companies Actavis and Merz told a New York federal court Tuesday they cannot be sued for "product hopping" the Alzheimer's treatment Namenda, because the drug's original version was never pulled off the market and a generic has since been released.